TuesdayJan 23, 2018 1:07 pm

Disrupting Drug Delivery Platform Keeps Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) Portfolio Growing

Patented technology promotes healthier administration of active pharmaceutical ingredients, including cannabidiol (CBD), psychoactive cannabinoids (THC), nicotine, fat soluble vitamins and nonsteroidal anti-inflammatory drugs Active pharmaceutical ingredient market expected to exceed $239 billion by 2025 19 patent applications filed in U.S. and internationally encompassing 44 countries Lab tests in 2018 include topical CBD skin cream, nicotine in edible formats Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is a research-driven company that has developed and out-licenses a patented drug delivery platform called DehydraTECH™ that changes the way active pharmaceutical ingredients (“APIs”) enter the body orally. According to a new report by Million…

Continue Reading

FridayJan 19, 2018 12:27 pm

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Combining Nature and Science to Make Life Better

Company utilizing novel Caribbean blue scorpion venom therapy for immune system boost PreveCeutical seeks new ways to treat cancers, metabolic disorders, pain, infectious diseases and cardiovascular disease Partnership with University of Queensland researchers advances scientific scope of projects In the modern health care industry, disease prevention has taken a commanding role as screenings and regularly scheduled physician visits aim to minimize costs that could otherwise spiral out of control once a chronic condition is established. However, the Centers for Disease Control and Prevention report an ongoing concern that Americans are using preventive services at about half the recommended rate (http://cnw.fm/OIa4V).…

Continue Reading

ThursdayJan 11, 2018 2:34 pm

2017 was a Transformative Year for Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Lexaria’s CEO posts end of 2017 summary Multiple transformative developments – IP strengthened, broad patents awarded, finances secured Foundation for the future established – multiple opportunities on horizon If the past is any prologue, Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) should have a break out year in 2018. Lexaria’s CEO, Chris Bunka, recently posted ‘LXRP CEO’s End of 2017 Summary’. It was a transformative year with multiple accomplishments that should establish a strong foundation for the future. Lexaria Bioscience has developed, patented and commercialized a cost-effective lipophilic delivery technology, DehydraTECH™, to enhance the performance of beneficial compounds in ingestible…

Continue Reading

TuesdayJan 02, 2018 2:36 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Marks Milestone with Patent Approval

LXRP awarded broad-ranging U.S. patent for novel DehydraTECH™ drug delivery system Already scientifically proven to increase efficacy of cannabinoids IP protection opens myriad business opportunities Food bioscience company Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) just hit another major milestone in the disruption of drug delivery and administration. With 19 international patent applications filed encompassing 44 countries, Lexaria recently announced its reception of a broad-ranging U.S. patent award for its DehydraTECH™ as a delivery platform for a wide variety of active pharmaceutical ingredients (http://cnw.fm/2KT1d). The U.S. patent covers all cannabinoids including THC, fat soluble vitamins, non-steroidal anti-inflammatory drugs (“NSAIDs”) and…

Continue Reading

WednesdayDec 27, 2017 1:05 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Says Best is yet to Come in 2018

DehydraTECH™ is the company’s newly U.S.-patented disruptive drug delivery platform; LXRP CEO Chris Bunka says company is working on more applications for its technology in the treatment of Alzheimer’s disease, Parkinson’s disease, opioid addiction and more LXRP has a portfolio of patents issued in both the U.S. and Australia, plus 19 patent applications filed in the U.S. (and internationally using the Patent Cooperation Treaty), as well as national filings in 44 countries Company has diverse revenue streams, including out-licensing its technology to third parties with fees ranging from five to 10 percent of gross sales, as well as sales of…

Continue Reading

TuesdayDec 26, 2017 2:38 pm

NeutriSci International, Inc. (OTCQB: NRXCF) (TSX.V: NU) (FRA: IN9) Completes Private Placement, Will Use Proceeds for Neuenergy® Marketing

Neuenergy is a chewable and revolutionary energy tablet powered by blueberries and anti-oxidants with no sugar or calories NeutriSci International names Glen Rehman as new CEO Company sees new opportunities for its product in the cannabinoid field, as well as new strategic partnerships NeutriSci International, Inc. (OTCQB: NRXCF) (TSX.V: NU) (FRANKFURT: IN9) recently announced that it has raised $499,999.95 in a non-brokered private placement (http://cnw.fm/C4cA1), with the proceeds to be used for marketing and advertising of Neuenergy®, its branded blueberry-powered energy chewable tablet (http://cnw.fm/Ll6n9). Funds will also go to the company for general corporate purposes. In addition, the company announced…

Continue Reading

FridayDec 22, 2017 10:26 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) and its Revolutionary Technology are Ready for the Cannabis Industry

Worldwide cannabis market expected to reach between $30 billion and $50 billion within four years Patent protected disruptive technology enables more efficient delivery and absorption of cannabinoids Groundbreaking delivery technology DehyraTECH™ positions Lexaria as potential M&A prospect Lexaria BioScience Corp. (CSE: LXX) (OTCQB: LXRP), a Canadian biosciences company that has developed delivery technologies to improve absorption of bioactive compounds, including cannabinoids, now has multiple patents pending in over 40 countries around the world. The company’s first patents, issued in the United States and Australia, relate to edible forms of cannabinoids or CBDs. Hot off a winning presentation at the 2017…

Continue Reading

TuesdayDec 12, 2017 2:24 pm

Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Aims to Enhance Opioid Analgesic Effects with Specific Cannabis Strain

Unique scientific approach lends more credibility and increases consumer confidence Huge potential for cannabis to replace opioids as analgesics Strategic partnerships position Veritas strongly in the medical cannabis industry On September 13, 2017, Cannevert Therapeutics Ltd. ("CTL"), the research arm of Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP), filed a provisional patent for the use of a specific strain of cannabis to enhance the actions of opioid analgesics. Opioid analgesics are traditionally prescribed for relief of acute and chronic pain. However, over-prescription or prolonged use can lead to addiction. Recreational users of opioids commonly run the risk of…

Continue Reading

FridayDec 08, 2017 11:00 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Partners with Stakeholders to Participate on Global Scale with DehydraTECH™

Amidst increasing awareness regarding potential health benefits of cannabinoids, Lexaria is at the forefront of a booming industry LXRP stakeholders have the opportunity to participate on a global scale to improve the delivery and performance of various products Lexaria’s patented technology provides an enabling layer in cannabinoid research and development, existing products and applications Amidst increasing awareness regarding cannabinoids and their potential health benefits, Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) is at the forefront of the booming cannabis industry with its patented delivery technology, DehydraTECH™. The technology provides an enabling layer to advances in cannabinoid research and development as…

Continue Reading

WednesdayDec 06, 2017 12:03 pm

Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Providing Clinical Proof of Cannabis Efficiency

Veritas Pharma is unlocking the science underlying medical cannabis Clinically profiling select cannabis strains - pharmacologically identifying strains for specific disease conditions Entering human clinical studies with valuable IP’s in place There is growing support for medicinal cannabis. Repeated peer-reviewed studies have demonstrated positive patient responses in a variety of maladies. However, to date, the response has been largely anecdotal, and, unlike rigorous pharmacology, the precise mechanisms and chemical profiles of cannabinoids remain unknown.  Through exacting scientific protocols, Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) is about to radically change the understanding and applications of this millennia-old medicine.…

Continue Reading

CanadianCannabisWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 905.674.5977